SAN DIEGO, April 9, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. ( Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14th, 2020 at 2:50 p.m. ET. The conference is being held in a virtual format.
A live webcast of the presentation will be available on the Company's website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.
For more information, visit www.herontx.com.
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Chief Legal, Business, and Administrative Officer
Heron Therapeutics, Inc.
SOURCE Heron Therapeutics, Inc.